Clinical Trial Update: Iressa Versus Docetaxel (Taxotere) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing gefitinib (Iressa) with docetaxel (Taxotere) for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED